Overview

Pragmatic Trial of Psilocybin Therapy in Palliative Care

Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Phase:
Phase 2
Details
Lead Sponsor:
Charles S. Grob, M.D.
Collaborator:
University of California, San Francisco
Treatments:
Hallucinogens
Ketamine
Psilocybin